SoftOx Solutions AS — Regulatory Filings 2021

Mar 23, 2021

SOFTOX SOLUTIONS AS HAS COMPLETED ENROLMENT OF SOFTOX WOUND IRRIGATION SOLUTION CONFIRMATORY STUDY (SWIS-02)

SOFTOX SOLUTIONS AS HAS COMPLETED ENROLMENT OF SOFTOX WOUND IRRIGATION SOLUTION CONFIRMATORY STUDY (SWIS-02)

SoftOx Solutions AS (“SoftOx”) is pleased to announce that the enrolment of study participants for the clinical investigation «SWIS-02» has been completed. The study, which has been conducted at Bispebjerg University Hospital is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution (“SWIS”) compared to Normal Saline (NS) in a human wound model. It is a confirmative study and last of two clinical studies on “SWIS”.

We are very pleased to have completed this enrolment because of the ongoing lockdown in Denmark, which were affecting our recruitment pace. “With this pivotal trial we are eagerly looking forward to examining and analyse the study data and report on the results later in Q2-2021”, says Glenn Gundersen, Medical Director of SoftOx.

SWIS is under development to become a medical device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or

Glenn Gundersen, Medical Director in SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS

SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth

Oslo. Our Vison is “Helping the world fighting infections - developing new ways

of eradicating infections and fighting antimicrobial resistance”. We are working

to combat major threats to human health, namely the emergence of antimicrobial

resistance (AMR), biofilm infections in chronic wounds and the spread of

viruses. For more information on SoftOx, visit www.soft-ox.com